https://scholars.lib.ntu.edu.tw/handle/123456789/477735
標題: | Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? | 作者: | WEI-WU CHEN CHING-HUNG LIN CHIUN-SHENG HUANG |
公開日期: | 2016 | 出版社: | AME Publishing Company | 卷: | 5 | 起(迄)頁: | S907-S912 | 來源出版物: | Translational Cancer Research | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996866550&doi=10.21037%2ftcr.2016.10.17&partnerID=40&md5=54b283fba59e78f712f294aa1541a35b https://scholars.lib.ntu.edu.tw/handle/123456789/477735 |
ISSN: | 2218-676X | DOI: | 10.21037/tcr.2016.10.17 | SDG/關鍵字: | epidermal growth factor receptor 2; pertuzumab; trastuzumab; adjuvant therapy; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer survival; drug use; human; long term survival; neoadjuvant therapy; Note; treatment response |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。